Evidence map›Paper›PMID 40092980›Full record

ReviewFrontiers in immunology2025

T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma.

Enrico Maggi, Nadine Landolina, Enrico Munari, Francesca Romana Mariotti, Nicola Tumino, Paola Vacca, Bruno Azzarone, Lorenzo Moretta

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Enrico MaggiTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Nadine LandolinaTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Enrico MunariDepartment of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
Francesca Romana MariottiTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Nicola TuminoInnate Lymphoid Cells Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola VaccaInnate Lymphoid Cells Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Bruno AzzaroneTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lorenzo MorettaTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma (NB) is an immunologically "cold" tumor with poor or no inflamed substrates as most of solid pediatric tumors (SPT). Consistent data indicate that NB tumor microenvironment (TME) is dominated by myeloid cells, with little (but variable) T cell infiltration. The obstacles to lymphocyte infiltration and to their anti-tumor activity are due to different tumor immune evasion strategies, including loss of HLA Class I molecules, high expression of immune checkpoint molecular ligands leading to exhaustion of T effector (and NK) cells, induction of T regulatory, myeloid and stromal cells and secretion of immunosuppressive mediators. In odds with adult solid tumors, NB displays weak immunogenicity caused by intrinsic low mutational burden and scant expression of neoepitopes in the context of MHC-class I antigens which, in turn, are particularly poorly expressed on NB cells, thus inducing low anti-tumor T cell responses. In addition, NB is generated from embryonal cells and is the result of transcriptional abnormalities and not of the accumulation of genetic mutations over time, thus further explaining the low immunogenicity. The poor expression of immunogenic molecules on tumor cells is associated with the high production of immunosuppressive factors which further downregulate lymphocyte infiltration and activity, thus explaining the limited efficacy of new drugs in NB, as immune checkpoint inhibitors. This review is focused on examining the role of T effector and regulatory cells infiltrating TME of NB, taking into account their repertoire, phenotype, function, plasticity and, importantly, predictive value for defining novel targets for therapy.

Indexed as

Lymphocytes, Tumor-InfiltratingNeuroblastomaT-LymphocytesTumor MicroenvironmentAnimalsChildHumansTumor Escapeimmunosuppressionimmunotherapy of tumorssolid pediatric tumorsT effector cellsT regulatory cellstumor infiltrating lymphocytes

Identifiers

PMID40092980
PMCPMC11906424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.